Survival in adult patients with BRAF V600 mutation-positive advanced melanoma: a non-interventional ambispective study of a cohort of patients treated with cobimetinib during the French early access program (TAU) FRESH-PEF74085-en Camille BACHOT Survival in adult patients with BRAF V600 mutation-positive advanced melanoma: a non-interventional ambispective study of a cohort of patients treated with cobimetinib during the French early access program (TAU) MELANIS FRESH-PEF74085-en 74085 FRESH-PEF74085 NCT03139513 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center cobimetinib Oncology Dermatology Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues Healthcare system determinants: Use of care Healthcare system determinants Primary Objective: To estimate the OS of patients treated with cobimetinib in combination with vemurafenib Secondary Objectives: - To assess the PFS - To identify prognostic factors of OS - To identify prognostic factors of PFS - To describe response to treatment (overall assessment of the physician) - To describe time to treatment discontinuation. - To characterize the targeted AE of cobimetinib in combination with vemurafenib under real-world conditions of useTo describe the long term safety profile of cobimetinib in association with vemurafenib under real-world conditions of use Exploratory Objectives: - To describe population of patients treated with cobimetinib in combination with vemurafenib - To describe the use of cobimetinib in combination with vemurafenib null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria: - Patients at least 18 years-old - Patients included in the TAU from 26 February 2015 - Patients with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with Zelboraf® (vemurafenib) - For alive patients: patients who have been informed verbally and in writing about this study who do not object to their data being electronically processed or subjected to data quality control and who have signed the consent form OR - For patients who died before the inclusion period: patients who did not expressed their opposition when they were alive. Alive patients unable to give informed consent- patients previously included in cobimetinib clinical trial. Clinical data Participant-reported health data CDISC like GCP/GVP Health event/morbidity Health event/mortality Health care consumption and services Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Converting or copying information into a structured record Observational Study Observational Study Cohort study 198 Unknown Restricted access Access on specific project only